Comparing safety and efficacy of melatonin, trazodone, and clonazepam on the sleep quality of patients with Parkinson's disease
Phase 3
Completed
- Conditions
- Sleep disorder of patients with Parkinson's disease.Parkinson's disease
- Registration Number
- IRCT20170821035819N2
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Patients with Parkinson's disease who have sleep disorder based on history.
Exclusion Criteria
Dementia
A history of drug sensitivity
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sleep quality. Timepoint: First time and After 1 month. Method of measurement: Pittsburgh sleep quality questionnaire.;Daytime sleepiness. Timepoint: First time and After 1 month. Method of measurement: Epworth sleepiness score questionnaire.;Sleep Disorder. Timepoint: First time and After 1 month. Method of measurement: REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie melatonin's efficacy in Parkinson's disease sleep disorders?
How does trazodone compare to clonazepam in managing sleep disturbances in Parkinson's disease patients?
Are there specific biomarkers that predict response to melatonin or trazodone in Parkinson's disease-related insomnia?
What are the potential adverse events associated with clonazepam use in Parkinson's disease and how can they be managed?
What combination therapies or alternative drugs show promise alongside melatonin for Parkinson's disease sleep disorders?